Altria Sues FDA, Alleging Flawed Review Process for New Nicotine Products

Tobacco giant Altria Group Inc. has filed a lawsuit against the U.S. Food and Drug Administration (FDA), seeking to compel a complete overhaul of the agency's review process for new nicotine products. The company alleges the current system has created significant regulatory delays, effectively blocking its newer products from reaching the market, according to a legal filing on Wednesday.

Details of the Complaint

In the complaint, filed in a federal court in Lubbock, Texas, Altria argues that the FDA's pre-market tobacco product application (PMTA) process is fundamentally broken. U.S. law requires the FDA to review new tobacco products to assess whether they offer a net public health benefit, such as helping adult smokers switch from traditional cigarettes.

Altria claims the agency has failed to meet its legal obligations, specifically highlighting:

• Missed Deadlines: The lawsuit states the FDA has consistently violated a legal requirement to make a decision on applications within 180 days, a deadline Altria claims the agency has never met.
• Market Disruption: The company contends that these delays have mired products like its On! nicotine pouches in "regulatory red tape."
• Unfair Competition: Altria alleges the FDA's inaction allows foreign competitors that have not complied with the rules to gain an unfair market advantage.

Ad

Market Implications and Context

For tobacco companies like Altria, the timely approval of new, non-combustible products is a critical part of their strategy to transition away from traditional cigarettes. Regulatory hurdles in the U.S., the largest market for these alternatives, represent a significant business risk for the industry.

Altria has asked the court to set aside the current review system and order the FDA to develop a new, more efficient one. The outcome of this lawsuit could have broad implications for the entire nicotine product industry in the United States. The FDA did not immediately respond to a request for comment on the litigation.